{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:44:56Z","timestamp":1788335096082,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) reflect axonal damage and astrocytic injury. Their clinical role in longitudinal real-world monitoring after immune reconstitution therapy (IRT) in multiple sclerosis (MS) remains insufficiently defined. We evaluated longitudinal sNfL and sGFAP dynamics in people with multiple sclerosis (pwMS) treated with alemtuzumab (ATZ) as a model of IRT to determine their prognostic and monitoring value in real-world care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PwMS initiating ATZ were prospectively followed up every three months for up to five years. sNfL and sGFAP levels were measured using single molecule array (Simoa) and converted to age- and BMI-adjusted Z scores based on healthy control datasets. Longitudinal trajectories were analysed with generalised linear mixed models adjusted for age, sex, and disease duration. Receiver operating characteristic (ROC) analysis with Youden\u2019s index identified optimal cut-offs for disease activity. Logistic and Cox regression models assessed predictive values. Event-related analyses examined biomarker changes around relapses, MRI activity, progression independent of disease activity (PIRA), and retreatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-four pwMS (mean age 36.5\u2009\u00b1\u20099.0 years, 76% female) were included. Baseline sNfL Z scores were significantly higher in males and in those with recent MRI activity or treatment failure. sNfL rose transiently one month after the first ATZ course, declined by month 3, and remained stably reduced thereafter. Youden\u2019s index-derived baseline sNfL Z scores\u2009\u2265\u20090.75 modestly predicted disease activity during year 1 (odds ratio: 5.10, 95% CI 1.79\u201314.49), and Z scores\u2009&gt;\u20091.0 predicted relapses after the first ATZ course (hazard ratio: 2.96, 95% confidence interval 1.36\u20136.43,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). Compared to matched pwMS without disease activity, event-related analyses showed significant sNfL elevations around relapses (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), MRI activity (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.015), and retreatment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). A transient increase was observed in the 6 months before PIRA events, followed by normalization (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.017). sGFAP levels remained overall stable over follow-up (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.677) and showed no predictive value.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>sNfL provided modest predictive and clear monitoring value in pwMS treated with ATZ and may complement individualized follow-up alongside clinical and MRI assessment. In contrast, sGFAP remained overall stable and did not associate with inflammatory events. However, a modest association with subclinical MRI activity was observed, suggesting further research is needed to fully understand the role of sGFAP in monitoring IRT-treated pwMS. These findings support the real-world clinical utility of high-frequency sNfL monitoring for early detection of breakthrough disease activity after IRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12974-025-03674-2","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T21:46:20Z","timestamp":1767131180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Longitudinal high-frequency blood biomarkers of axonal injury and astrocytic activation after immune reconstitution in multiple sclerosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Hernan","family":"Inojosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Werder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Haase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Undine","family":"Proschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Benkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen B","family":"Huttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjalf","family":"Ziemssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Akg\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"8","key":"3674_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: A review. JAMA. 2021;325(8):765\u201379.","journal-title":"JAMA"},{"key":"3674_CR2","doi-asserted-by":"crossref","unstructured":"Pitt D, Lo CH, Gauthier SA, Hickman RA, Longbrake E, Airas LM, Toward Precision Phenotyping of Multiple Sclerosis. Neurology(R), neuroimmunology et al. & neuroinflammation. 2022;9(6):e200025.","DOI":"10.1212\/NXI.0000000000200025"},{"issue":"10","key":"3674_CR3","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, et al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):e1007\u201315.","journal-title":"Neurology"},{"key":"3674_CR4","doi-asserted-by":"crossref","unstructured":"Barro C, Healy BC, Liu Y, Saxena S, Paul A, Polgar-Turcsanyi M et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurology(R) Neuroimmunol Neuroinflammation. 2023;10(1):e200052.","DOI":"10.1212\/NXI.0000000000200052"},{"issue":"12","key":"3674_CR5","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1212\/01.WNL.0000098880.19793.B6","volume":"61","author":"C Malmestrom","year":"2003","unstructured":"Malmestrom C, Haghighi S, Rosengren L, Andersen O, Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology. 2003;61(12):1720\u20135.","journal-title":"Neurology"},{"issue":"1","key":"3674_CR6","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","volume":"8","author":"A Abdelhak","year":"2018","unstructured":"Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798.","journal-title":"Sci Rep"},{"issue":"22","key":"3674_CR7","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/WNL.0000000000004683","volume":"89","author":"L Novakova","year":"2017","unstructured":"Novakova L, Zetterberg H, Sundstr\u00f6m P, Axelsson M, Khademi M, Gunnarsson M, et al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230\u20137.","journal-title":"Neurology"},{"issue":"3","key":"3674_CR8","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli \u00d6, Maceski A, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246\u201357.","journal-title":"Lancet Neurol"},{"key":"3674_CR9","doi-asserted-by":"crossref","unstructured":"Benkert P, Maleska Maceski A, Schaedelin S, Oechtering J, Zadic A, Vilchez Gomez JF et al. Serum glial fibrillary acidic protein and neurofilament light chain levels reflect different mechanisms of disease progression under B-Cell depleting treatment in multiple sclerosis. Ann Neurol. 2024;97(1):104\u201315.","DOI":"10.1002\/ana.27096"},{"issue":"3","key":"3674_CR10","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1212\/NXI.0000000000000555","volume":"6","author":"K Akgun","year":"2019","unstructured":"Akgun K, Kretschmann N, Haase R, Proschmann U, Kitzler HH, Reichmann H, et al. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurology(R) Neuroimmunol Neuroinflammation. 2019;6(3):e555.","journal-title":"Neurology(R) Neuroimmunol Neuroinflammation"},{"issue":"4","key":"3674_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/13524585211032348","volume":"28","author":"J Kuhle","year":"2022","unstructured":"Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, et al. Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS. Mult Scler. 2022;28(4):573\u201382.","journal-title":"Mult Scler"},{"key":"3674_CR12","doi-asserted-by":"publisher","first-page":"1265354","DOI":"10.3389\/fneur.2023.1265354","volume":"14","author":"S Sandgren","year":"2023","unstructured":"Sandgren S, Novakova L, Nordin A, Axelsson M, Malmestr\u00f6m C, Zetterberg H, et al. A five-year observational prospective mono-centre study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis. Front Neurol. 2023;14:1265354.","journal-title":"Front Neurol"},{"key":"3674_CR13","doi-asserted-by":"publisher","first-page":"117079","DOI":"10.1016\/j.jns.2020.117079","volume":"417","author":"V Anderson","year":"2020","unstructured":"Anderson V, Bentley E, Loveless S, Bianchi L, Harding KE, Wynford-Thomas RA, et al. Serum neurofilament-light concentration and real-world outcome in MS. J Neurol Sci. 2020;417:117079.","journal-title":"J Neurol Sci"},{"key":"3674_CR14","doi-asserted-by":"publisher","first-page":"104210","DOI":"10.1016\/j.msard.2022.104210","volume":"68","author":"C Zjukovskaja","year":"2022","unstructured":"Zjukovskaja C, Larsson A, Cherif H, Kultima K, Burman J. Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis. Multiple Scler Relat Disorders. 2022;68:104210.","journal-title":"Multiple Scler Relat Disorders"},{"issue":"5","key":"3674_CR15","first-page":"e598","volume":"6","author":"S Thebault","year":"2019","unstructured":"Thebault S, Tessier R, Lee D, Bowman H, Bar-Or M, Arnold A, et al. DL, High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurology: Neuroimmunol Neuroinflammation. 2019;6(5):e598.","journal-title":"Neurology: Neuroimmunol Neuroinflammation"},{"issue":"6","key":"3674_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1177\/1352458519840757","volume":"26","author":"JW Hyun","year":"2020","unstructured":"Hyun JW, Kim Y, Kim G, Kim SH, Kim HJ. Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis. Mult Scler. 2020;26(6):659\u201367.","journal-title":"Mult Scler"},{"key":"3674_CR17","doi-asserted-by":"publisher","first-page":"1454474","DOI":"10.3389\/fimmu.2024.1454474","volume":"15","author":"R Sainz-Amo","year":"2024","unstructured":"Sainz-Amo R, Rodero Romero A, Monreal E, Chico Garc\u00eda JL, Fern\u00e1ndez Velasco JI, Villarrubia N, et al. Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis. Front Immunol. 2024;15:1454474.","journal-title":"Front Immunol"},{"issue":"1","key":"3674_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40893-018-0037-7","volume":"3","author":"S Ruggieri","year":"2018","unstructured":"Ruggieri S, Pontecorvo S, Tortorella C, Gasperini C. Induction treatment strategy in multiple sclerosis: a review of past experiences and future perspectives. Multiple Scler Demyelinating Disorders. 2018;3(1):5.","journal-title":"Multiple Scler Demyelinating Disorders"},{"key":"3674_CR19","doi-asserted-by":"crossref","unstructured":"Ruder J, Dinner G, Maceski A, Berenjeno-Correa E, M\u00fcller AM, Jelcic I et al. Dynamics of inflammatory and neurodegenerative biomarkers after autologous hematopoietic stem cell transplantation in multiple sclerosis. Int J Mol Sci. 2022;23(18):10946.","DOI":"10.3390\/ijms231810946"},{"issue":"17","key":"3674_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","volume":"359","author":"AJ Coles","year":"2008","unstructured":"Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786\u2013801.","journal-title":"N Engl J Med"},{"issue":"9856","key":"3674_CR21","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (London England). 2012;380(9856):1819\u201328.","journal-title":"Lancet (London England)"},{"issue":"9856","key":"3674_CR22","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829\u201339.","journal-title":"Lancet"},{"issue":"4","key":"3674_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1177\/2211068215589580","volume":"21","author":"DH Wilson","year":"2016","unstructured":"Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, et al. The Simoa HD-1 analyser: A novel fully automated digital immunoassay analyser with Single-Molecule sensitivity and multiplexing. SLAS Technol. 2016;21(4):533\u201347.","journal-title":"SLAS Technol"},{"key":"3674_CR24","unstructured":"Maceski AM, Benkert P, Oechtering J, Sch\u00e4delin S, Zadic A, Vilchez Gomez JF et al. Serum glial fibrillary acidic protein (sGFAP) levels are reduced by Fingolimod treatment and prognosticate disease progression independent of relapse activity in multiple sclerosis. O059\/1356, ECTRIMS 2024 \u2013 Oral Presentations. 2024."},{"key":"3674_CR25","doi-asserted-by":"crossref","unstructured":"Maceski AM, Benkert P, Einsiedler M, Schaedelin S, Oechtering J, Melie-Garcia L et al. GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis. Brain. 2025:awaf433. Epub ahead of print.","DOI":"10.1093\/brain\/awaf433"},{"key":"3674_CR26","doi-asserted-by":"publisher","first-page":"894119","DOI":"10.3389\/fneur.2022.894119","volume":"13","author":"N R\u00fcbsamen","year":"2022","unstructured":"R\u00fcbsamen N, Willemse EA, Leppert D, Wiendl H, Nauck M, Karch A, et al. A method to combine neurofilament light measurements from blood serum and plasma in clinical and population-based studies. Front Neurol. 2022;13:894119.","journal-title":"Front Neurol"},{"issue":"7","key":"3674_CR27","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1177\/1352458517709619","volume":"24","author":"L Kappos","year":"2018","unstructured":"Kappos L, Butzkueven H, Wiendl H, Spelman T, Pellegrini F, Chen Y, et al. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Mult Scler. 2018;24(7):963\u201373.","journal-title":"Mult Scler"},{"issue":"2","key":"3674_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1352458518819380","volume":"26","author":"H H\u00f6gel","year":"2020","unstructured":"H\u00f6gel H, Rissanen E, Barro C, Matilainen M, Nylund M, Kuhle J, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. 2020;26(2):210\u20139.","journal-title":"Mult Scler"},{"issue":"6","key":"3674_CR29","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A, et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017;81(6):857\u201370.","journal-title":"Ann Neurol"},{"key":"3674_CR30","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fneur.2020.00608","volume":"11","author":"A Huss","year":"2020","unstructured":"Huss A, Otto M, Senel M, Ludolph AC, Abdelhak A, Tumani H. A score based on NfL and glial markers May differentiate between Relapsing-Remitting and progressive MS course. Front Neurol. 2020;11:608.","journal-title":"Front Neurol"},{"key":"3674_CR31","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/NDT.S173280","volume":"14","author":"L Cai","year":"2018","unstructured":"Cai L, Huang J. Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study. Neuropsychiatr Dis Treat. 2018;14:2241\u201354.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"3674_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1177\/1352458512443092","volume":"18","author":"CE Teunissen","year":"2012","unstructured":"Teunissen CE, Khalil M. Neurofilaments as biomarkers in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). 2012;18(5):552\u20136.","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)"},{"issue":"10","key":"3674_CR33","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1177\/1352458520972573","volume":"27","author":"PA de Calabresi","year":"2021","unstructured":"Calabresi PA, Arnold DL, Sangurdekar D, Singh CM, Altincatal A, de Moor C et al. Temporal profile of serum neurofilament light in multiple sclerosis: implications for patient monitoring. Multiple sclerosis (Houndmills, Basingstoke, England). 2021;27(10):1497\u2013505.","journal-title":"Multiple sclerosis (Houndmills, Basingstoke, England)."},{"issue":"10","key":"3674_CR34","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/acn3.52187","volume":"11","author":"E Madill","year":"2024","unstructured":"Madill E, Healy BC, Molazadeh N, Polgar-Turcsanyi M, Glanz BI, Weiner HL, et al. Serum glial fibrillary acidic protein predicts disease progression in multiple sclerosis. Ann Clin Transl Neurol. 2024;11(10):2719\u201330.","journal-title":"Ann Clin Transl Neurol"},{"key":"3674_CR35","doi-asserted-by":"crossref","unstructured":"Shaygannejad A, Rafiei N, Vaheb S, Yazdan Panah M, Shaygannejad V, Mirmosayyeb O. The Role of Glial Fibrillary Acidic Protein as a Biomarker in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis. Medicina (Kaunas). 2024;60(7):1050.","DOI":"10.3390\/medicina60071050"},{"issue":"5","key":"3674_CR36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/acn3.51045","volume":"7","author":"S Thebault","year":"2020","unstructured":"Thebault S, Lee H, Bose G, Tessier D, Abdoli M, Bowman M, et al. Neurotoxicity after hematopoietic stem cell transplant in multiple sclerosis. Ann Clin Transl Neurol. 2020;7(5):767\u201375.","journal-title":"Ann Clin Transl Neurol"},{"key":"3674_CR37","doi-asserted-by":"crossref","unstructured":"Seiberl M, Feige J, Hilpold P, Hitzl W, Machegger L, Buchmann A et al. Serum neurofilament light chain as biomarker for Cladribine-Treated multiple sclerosis patients in a Real-World setting. Int J Mol Sci. 2023;24(4):4067.","DOI":"10.3390\/ijms24044067"},{"key":"3674_CR38","doi-asserted-by":"crossref","unstructured":"Paolicelli D, Ruggieri M, Manni A, Gargano CD, Carleo G, Palazzo C et al. Real-Life experience of the effects of cladribine tablets on lymphocyte subsets and serum neurofilament light chain levels in relapsing multiple sclerosis patients. Brain Sci. 2022;12(12):1595.","DOI":"10.3390\/brainsci12121595"},{"key":"3674_CR39","doi-asserted-by":"publisher","first-page":"175628642513517","DOI":"10.1177\/17562864251351760","volume":"18","author":"K Schmierer","year":"2025","unstructured":"Schmierer K, Wiendl H, Barkhof F, Montalban X, Achiron A, Derfuss T, et al. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study. Ther Adv Neurol Disord. 2025;18:17562864251351760.","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"3674_CR40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1136\/jnnp.64.3.402","volume":"64","author":"JN Lycke","year":"1998","unstructured":"Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998;64(3):402\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"3674_CR41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/ene.13274","volume":"24","author":"I Hakansson","year":"2017","unstructured":"Hakansson I, Tisell A, Cassel P, Blennow K, Zetterberg H, Lundberg P, et al. Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. Eur J Neurol. 2017;24(5):703\u201312.","journal-title":"Eur J Neurol"},{"issue":"3","key":"3674_CR42","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier S, Willemse EAJ, Schaedelin S, Oechtering J, Lorscheider J, Melie-Garcia L, et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 2023;80(3):287\u201397.","journal-title":"JAMA Neurol"},{"issue":"9","key":"3674_CR43","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000142988.49341.D1","volume":"63","author":"N Norgren","year":"2004","unstructured":"Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology. 2004;63(9):1586\u201390.","journal-title":"Neurology"},{"issue":"11","key":"3674_CR44","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","volume":"267","author":"B Steingo","year":"2020","unstructured":"Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fern\u00e1ndez \u00d3, et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020;267(11):3343\u201353.","journal-title":"J Neurol"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-025-03674-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03674-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-025-03674-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:59:49Z","timestamp":1781625589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-025-03674-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3674"],"URL":"https:\/\/doi.org\/10.1186\/s12974-025-03674-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7736188\/v1","asserted-by":"object"}]},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. The manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. HI received speaker honoraria from Roche and financial support for research activities from Merck, Neuraxpharm, Novartis, Teva, Biogen, and Alexion. UP received personal consulting fees from Biogen, Roche, and Sanofi and personal payment for speakers bureaus from Novartis, Merck, Biogen, Bayer, and Roche. JK reported grants from Biogen, Bristol Myers Squibb, Merck, Novartis, the Progressive MS Alliance, Quanterix, Roche, Stata DX, the Swiss MS Society, and the Swiss National Research Foundation and personal fees from Alnylam, Immunic, Merck, and Neurogenesis outside the submitted work. HBH reports financial suppor for research activities from Novartis. TZ reports scientific advisory board and\/or consulting for Biogen, Roche, Novartis, Celgene, and Merck; compensation for serving on speakers bureaus for Roche, Novartis, Merck, Sanofi, Celgene, and Biogen; and research support from Biogen, Novartis, Merck, and Sanofi. K.A. received personal compensation from Novartis, Biogen Idec, Teva, Sanofi, and Roche for consulting services. LW and RH have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}